COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Results Conference Call May 8, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Ritu Baral - TD Cowen Charles Duncan - Cantor Patrick Trucchio - H.C. Wainwright & Co. Tom Shrader - BTIG Sumant Kulkarni - Canaccord Genuity Elemer Piros - Rodman Operator Thank you for standing by, and welcome to the COMPASS Pathways' First Q ...

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights • Cash position of $262.9 million at March 31, 2024 London, UK – May 8, 2024 Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2024 and provided an update on recent business progress. COMP360 psilocybin treatment in treatment-resistant depression (TRD): ...

England and Wales Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 33 Broadwick Street London W1F 0DQ United Kingdom (Address of principal executive offices, zip code) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was ...

COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8 at 8:00 am E ...

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12 Measures of symptom scores relative t ...

LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2024 ending March 31, 2024, and provide an update on recent business developments, on May 8, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2024. To access the call, please register in advance here to o ...

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US's leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement to inform the development of a scalable and cost-effective delivery model for COMP360 psilocybin treatment, if approved for ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to inform the development of a scalable and practical delivery and healthcar ...

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President, Investor Relations Kabir Nath - Chief Executive Officer Mary-Rose Hughes - Interim Financial Officer Teri Loxam - Incoming Chief Financial Officer Dr. Guy Goodwin - Chief Medical Officer Conference Call Participants Patrick Trucchio - H.C. Wainright Charles Duncan - Cantor François Brisebois - Oppenheimer Neena Bitritto-Garg - Deutsche Bank Ritu Baral ...

• Publication of results of COMP360 treatment in bipolar II depression published in JAMA Psychiatry showing a significant number of patients experience relief from their bipolar II depression symptoms after a single 25mg dose of COMP360 psilocybin treatment. 2 • Long term debt was $28.8 million as of December 31, 2023, compared with $0 million as of December 31, 2022 • Additional $31.4 million net cash raised to date in first quarter 2024 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------ ...